Haptoglobin Therapeutics and Compartmentalization of Cell-Free Hemoglobin Toxicity
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2020Journal
Trends in Molecular MedicinePublisher
Elsevier LtdType
Article
Metadata
Show full item recordAbstract
Hemolysis and accumulation of cell-free hemoglobin (Hb) in the circulation or in confined tissue compartments such as the subarachnoid space is an important driver of disease. Haptoglobin is the Hb binding and clearance protein in human plasma and an efficient antagonist of Hb toxicity resulting from physiological red blood cell turnover. However, endogenous concentrations of haptoglobin are insufficient to provide protection against Hb-driven disease processes in conditions such as sickle cell anemia, sepsis, transfusion reactions, medical-device associated hemolysis, or after a subarachnoid hemorrhage. As a result, there is increasing interest in developing haptoglobin therapeutics to target 'toxic' cell-free Hb exposures. Here, we discuss key concepts of Hb toxicity and provide a perspective on the use of haptoglobin as a therapeutic protein. Copyright 2020 The AuthorsKeyword
haptoglobinheme
hemoglobin
hemolysis
sepsis
sickle cell disease
subarachnoid hemorrhage
transfusion
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082015509&doi=10.1016%2fj.molmed.2020.02.004&partnerID=40&md5=7a61cc33ace36afc4b1675da5da39a86; http://hdl.handle.net/10713/12471ae974a485f413a2113503eed53cd6c53
10.1016/j.molmed.2020.02.004